Entrada Therapeutics (TRDA) FY Conference June 09, 2025 08:00 AM ET Speaker0 Conference. My name is Paul Choi, and I cover the biotechnology sector here at the firm. And it's my pleasure to welcome Entrada for our first session to kick off the conference. Before we begin, I'm required to make certain disclosures regarding Goldman Sachs' relationships with certain companies that may be attending or presenting here at the conference. Those relationships include investment banking, 1% or more ownership of the ...

Entrada Therapeutics (TRDA) 2025 Conference June 04, 2025 11:05 AM ET Speaker0 Hang on one second. Nope. Which button? Is it the green? Well, they're all green. Oh, the big green. Okay. Before I begin, I just need to remind you that during the presentation, I'll be making forward looking statements. So please refer to our public SEC disclosures. We're progressing '25 through '25 in a very quick and efficient manner. And there's a lot of momentum that's building for the company as I speak today. So by the en ...

BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 23,820 restricted stock units (“RSUs”) to six newly-hired non-executive employees under the Company’s 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of June 1, 2025. The inducement grants were previously approved by the Compensation Committee of the Company’s Board of Directors, as a material inducement to the new employees’ entry into employment wit ...

About ENTR-601-45 ENTR-601-45, a proprietary Endosomal Escape Vehicle (EEV™)-conjugated phosphorodiamidate morpholino oligomer (PMO), is the second product candidate within Entrada's Duchenne muscular dystrophy franchise from its growing pipeline of EEV-therapeutics. Each EEV-PMO therapeutic candidate has an oligonucleotide sequence designed and optimized for the specific subpopulation of interest. ENTR-601-45 is designed to address the underlying cause of Duchenne due to mutated or missing exons in the DMD ...

Entrada Therapeutics (TRDA) FY 2025 Conference May 20, 2025 02:00 PM ET Speaker0 Hello, and welcome to the latest in this series of fireside chats here at the H. C. Wainwright BioConnect Conference. Thank you very much all for joining us. My name is Ram Selvaraju, and I'm a Managing Director and Senior Healthcare Equity Research Analyst within Wainwright's Equity Research Department. I'm joined here today by the next in our series of presenting companies, Entrada Therapeutics, represented by Nathan Dowden, ...

Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to earnings of $0.68 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 46.15%. A quarter ago, it was expected that this company would post a loss of $0.66 per share when it actually produced earnings of $0.03, delivering a surprise of 104.55%.Over the last four quarters, the co ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 10-Q ____________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-40969 ___________________ ...

– Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skipping – – Company remains on track to initiate ELEVATE-44-201 and ELEVATE-45-201 in Q2 and Q3 2025, respectively – – Cash runway expected into Q2 2027 with $383 million in cash, cash equivalents and marketable securities as of March 31, 2025 – BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nas ...

– Company on track to initiate ELEVATE-45-201 study in Q3 2025 – – ELEVATE-45 regulatory filings submitted in the EU, with regulatory review ongoing –  – ELEVATE-45 is the second of three novel exon skipping Duchenne programs the Company expects to progress into global clinical development in 2025 – BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced it has received authorization from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MH ...

Entrada Therapeutics, Inc. (TRDA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.66 per share. This compares to loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 104.55%. A quarter ago, it was expected that this company would post a loss of $0.67 per share when it actually produced a loss of $0.35, delivering a surprise of 47.76%.Over the last four quarters ...